Skip to main content

Audrey Andrews


Authored Items
Treating with Checkpoint Inhibitors—Figure $1 Million per Patient
Audrey Andrews
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
ASCO and NCI Launch Largest Precision Medicine Trials Using Real-World Evidence
Audrey Andrews
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
FDA Approves Mirvaso, First and Only Treatment Available for Erythema in Rosacea
Audrey Andrews
Payer Perspectives in Dermatology in Dermatology
Experts Debate Value of Bevacizumab in Newly Diagnosed Glioblastoma
Audrey Andrews
August 2013 Vol 6, No 6 Special Issue
Sorafenib Effective in Metastatic Differentiated Thyroid Cancer
Audrey Andrews
August 2013 Vol 6, No 6 Special Issue
Nearly 1 in 5 Patients with Cancer Reports Financial Distress
Audrey Andrews
August 2013 Vol 6, No 6 Special Issue
Immunotherapies Take Center Stage in Melanoma
Audrey Andrews
August 2013 Vol 6, No 6 Special Issue in Melanoma, Oncology
Four-Drug Induction and 2-Drug Maintenance Boost Overall Survival in Patients with Newly Diagnosed Myeloma
Audrey Andrews
February 2013 Vol 6, No 1, Special Issue in Multiple Myeloma, Oncology
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
Audrey Andrews
February 2013 Vol 6, No 1, Special Issue in Leukemia, Oncology
Ibrutinib: It’s Not Just for Leukemia
Audrey Andrews
February 2013 Vol 6, No 1, Special Issue in Leukemia, Oncology
Ara-C Should Be Part of Conditioning Regimen in Young Patients with Mantle-Cell Lymphoma
Audrey Andrews
February 2013 Vol 6, No 1, Special Issue in Lymphoma
Novel T-DM1 Prolongs Remission in Metastatic Breast Cancer: A New “Smart Bomb”
Audrey Andrews
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Breast Cancer, Oncology
Novel Agents Boost Survival in Metastatic Melanoma
Audrey Andrews
August 2011 Vol 4, No 4, Special Issue in Melanoma, Oncology
Last modified: September 6, 2011